Effect Of Endostar Combined With Gefitinib On Multiple Brain Metastases Of Non-Small Cell Lung Cancer After Whole Brain Radiotherapy

Objective: To investigate the application value of endostar combined with gefitinib in patients with multiple brain metastases from non-small cell lung cancer (NSCLC) undergoing whole brain radiotherapy and the correlation analysis with serum VEGF-C and CEA levels. Methods: A total of 87 patients with multiple brain metastases from NSCLC who were admitted to our hospital from December 2016 to October 2018 were selected as the research subjects. Among them, 40 patients who only received whole brain radiotherapy, were included in the control group (CG). Another 47 patients who were treated with endostar combined with gefitinib in addition to whole brain radiotherapy, were regarded as the research group (RG). The clinical efficacy and complications were compared between the two groups. During treatment, the changes and relationships of serum VEGF-C and CEA levels were analyzed. Results: There was no difference in complications and half-year survival rate between the two groups (P < 0.050), while the efficacy and one-year survival rate of prognosis in the RG were better than those in the CG (P < 0.050). After treatment, VEGF-C and CEA decreased (P < 0.050), which was negatively correlated with treatment time (P < 0.050). Conclusion: Endostar combined with gefitinib has significant curative effects and better prognosis in NSCLC patients with multiple brain metastases undergoing whole brain radiotherapy, it can also effectively reduce serum VEGF-C and CEA levels, and as such it is worthy of clinical application.